Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers

Yanhui Lu, Edward J Fuchs, Craig Walter Hendrix and Namandje N Bumpus
Drug Metabolism and Disposition August 12, 2014, dmd.114.060194; DOI: https://doi.org/10.1124/dmd.114.060194
Yanhui Lu
1 Johns Hopkins University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward J Fuchs
1 Johns Hopkins University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Walter Hendrix
2 Johns Hopkins Medical Institutions
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Namandje N Bumpus
1 Johns Hopkins University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nbumpus1@jhmi.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Cytochrome P450 3A5 (CYP3A5) plays a prominent role in oxidative metabolism of maraviroc, an approved drug for HIV-1 treatment and a candidate for HIV-1 prevention. We studied the effect of CYP3A5 genotype on pharmacokinetics of maraviroc and a primary CYP3A5-dependent metabolite of maraviroc denoted as metabolite 1 (M1). Volunteers were screened for health status and CYP3A5 genotype (wild type allele *1 and non-functional mutant alleles *2, *3, *6, and *7) to obtain 24 evaluable subjects in 3 groups (N = 8 each): mutant, heterozygous, and homozygous wild type. Subjects received an oral 300-mg maraviroc dose followed by blood collection for 32 h. The homozygous wild type group exhibited lower mean plasma maraviroc concentrations at almost all sampling times. The median (interquartile range) maraviroc area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) was 2099 (1422-2568) ng·h/mL, 1761 (931-2640) ng·h/mL and 1238 (1065-1407) ng·h/mL, respectively, for the mutant, heterozygous, and homozygous wild type groups. The homozygous wild type group had 41% lower maraviroc AUC0-inf, 66% higher apparent clearance, and 78% higher apparent volume of distribution, compared with mutant group (P ≤ 0.02). The AUC0-inf ratios of maraviroc to M1 in heterozygous and homozygous wild type group were lower by 51% and 64% when compared with the mutant group, respectively (P < 0.001). In conclusion, the lower maraviroc concentrations in the homozygous wild type group indicated that maraviroc may be under-dosed in people homozygous for CYP3A5*1 allele which includes almost a half of African Americans.

  • cytochrome P450
  • pharmacogenetics/pharmacogenomics
  • pharmacokinetics
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Drug Metabolism and Disposition: 49 (3)
Drug Metabolism and Disposition
Vol. 49, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers

Yanhui Lu, Edward J Fuchs, Craig Walter Hendrix and Namandje N Bumpus
Drug Metabolism and Disposition August 12, 2014, dmd.114.060194; DOI: https://doi.org/10.1124/dmd.114.060194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers

Yanhui Lu, Edward J Fuchs, Craig Walter Hendrix and Namandje N Bumpus
Drug Metabolism and Disposition August 12, 2014, dmd.114.060194; DOI: https://doi.org/10.1124/dmd.114.060194
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Clearance pathways: fevipiprant with probenecid perpetrator
  • Predicting Volume of Distribution from In Vitro Parameters
  • In Vivo Functional Effects of CYP2C9 M1L
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics